Affimed
Latest round
- Series E
Last raised
- Jul 2014
Total raised
- $97M
Investors
- 9
About Affimed
Based in Heidelberg, Germany, and founded in 2000 by Melvyn Little, Affimed GmbH is a biopharmaceutical company engaged in developing unique antibody formats for the treatment of cancer, such as hematological and solid tumors as well as for inflammatory diseases. The company trades on Nasdaq under the ticker symbol AFMD. As of November 2021, Affimed GmbH employees approximately 153 employees and Adi Hoess is the CEO of the company. Affimed GmbH develops multiple innate cell engagers, such as AFM13, AFM13 + Adoptive NK cells, AFM13 + ANTI-PD-1, AFM24, AFM24 + Adoptive NK cells, AFM24 + ANTI-PD-L1, AFM28, AFM32, Genentech, and ICE+ NK cell combination. AFM13 is ICE® (innate cell engager) molecule that benefits patients with CD30+ lymphomas. AFM24 is an EGFR-binding ICE® (innate cell engager) molecule that kills EGFR-expressing tumors. In addition, the company’s technology comprises ROCK® (redirected optimized cell-killing) platform that allows a molecular approach to generate customizable ICE® molecules.360 million in the fiscal year ended in December 2020.
Who invested in Affimed
9 investors across 5 rounds
See all investors in Affimed
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Affimed
Who invested in Affimed?
Affimed has 9 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Affimed raised?
Affimed has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Affimed last raise money?
Affimed's most recent round on record is a Series E, in Jul 2014.
What does Affimed do?
Based in Heidelberg, Germany, and founded in 2000 by Melvyn Little, Affimed GmbH is a biopharmaceutical company engaged in developing unique antibody formats for the treatment of cancer, such as hematological and solid tumors as well as for inflammatory diseases.
Where is Affimed headquartered?
Affimed is headquartered in Mannheim, Germany.
Which VCs invest in companies like Affimed?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Affimed's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Affimed? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.